Moneycontrol PRO
Loans
Loans
HomeNewsAjantapharma

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang

    Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang

    Net Sales are expected to increase by 9.6 percent Y-o-Y (up 18.2 percent Q-o-Q) to Rs 1,042.3 crore, according to Nirmal Bang.

  • Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct

    Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct

    Net Sales are expected to increase by 13.9 percent Y-o-Y (down 2.1 percent Q-o-Q) to Rs 852.3 crore, according to ICICI Direct.

  • Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct

    Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct

    Net Sales are expected to decrease by 11 percent Y-o-Y (down 3.9 percent Q-o-Q) to Rs. 522.6 crore, according to ICICI Direct.

  • Ajanta Pharma Q2 PAT may dip 16.5% YoY to Rs. 110.1 cr: ICICI Direct

    Ajanta Pharma Q2 PAT may dip 16.5% YoY to Rs. 110.1 cr: ICICI Direct

    Net Sales are expected to decrease by 4.4 percent Y-o-Y (up 1.1 percent Q-o-Q) to Rs. 516.6 crore, according to ICICI Direct.

  • R&D spends weighed heavily on Q4 margins: Ajanta Pharma

    R&D spends weighed heavily on Q4 margins: Ajanta Pharma

    The pharma company had posted strong fourth quarter profits but margins had contracted. The R&D spend for the quarter stood at 9 percent, says Yogesh M Agrawal, Managing Director of the company.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347